Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
ReplyLetter

Dr. Seidman replies

ERNEST SEIDMAN
The Journal of Rheumatology February 2019, 46 (2) 216; DOI: https://doi.org/10.3899/jrheum.180833
ERNEST SEIDMAN
Research Institute of the McGill University Health Centre, Division of Gastroenterology, 1650 Cedar Ave., C10.145, Montreal, Quebec H3G 1A4, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for ERNEST SEIDMAN
  • For correspondence: ernest.seidman@mcgill.ca
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

We are pleased to note the interest that Van Hoovels and colleagues have for our SpACE Capsule study1, and read with interest their investigation of the clinical utility of assaying fecal calprotectin (FC) to assist in the diagnosis of spondyloarthritis (SpA)2. Rheumatologists traditionally proclaim that the extraarticular manifestations of SpA include inflammatory bowel disease (IBD)3. IBD, including Crohn disease (CD) and ulcerative colitis, are analogously associated with various extraintestinal manifestations (EIM). The most common EIM is articular involvement, reported in 16–33% of patients with IBD4. Thus, gastroenterologists often decree SpA as an EIM of IBD. Regardless of which side of this “chicken and egg” debate one adheres to, the unifying message is that SpA and IBD often coexist and need to be assessed, because jointly they modify management strategies5,6.

FC is established as an excellent biomarker of intestinal inflammation7. Van Hoovels, et al investigated the value of FC in diagnosing suspected SpA. FC, in combination with imaging studies [plain radiograph and/or magnetic resonance imaging (MRI)], improved the diagnostic sensitivity of SpA2. In patients with both radiological and HLA-B27 testing, sensitivity and specificity were 67% and 84%, respectively. Adding FC increased the sensitivity to 74%, with specificity unchanged2. Based on their findings, the authors recommend endoscopic investigation of SpA patients with an elevated FC. Their observation is in keeping with our prospective SpACE Capsule study, which showed that FC was clinically useful in screening for IBD in established SpA1. We found that an elevated FC was associated with CD (OR 4.5, sensitivity 74%). We reported a significantly higher detection rate of CD in patients with SpA using videocapsule endoscopy (42%), compared to traditional colonoscopy (11%). No correlation was observed with the presence of GI symptoms, C-reactive protein, or IBD serology. Finding CD in patients with SpA led to a change in management in 65% of cases1.

There are certain limitations to the Van Hoovels group’s conclusions. The FC level, although elevated in the group diagnosed with SpA, was within the normal range for most patients. Moreover, there are concerns regarding the potential to overdiagnose axial spondyloarthritis (axSpA). In the Van Hoovels study, the final diagnosis of SpA was based on expert opinion2. Recently, Ez-Zaitonie, et al8 prospectively investigated whether patients presenting with chronic back pain (CBP) of short duration and many SpA features are uniformly diagnosed with axSpA by the rheumatologist, and to what extent fulfillment of the Assessment of Spondyloarthritis international Society (ASAS) axSpA criteria is associated with an axSpA diagnosis. Data from 500 patients of the Spondyloarthritis Caught Early cohort, which includes patients with CBP (≥ 3 mos, ≤ 2 yrs, onset < 45 yrs) were analyzed. Importantly, all patients underwent a complete diagnostic examination, including MRI of the sacroiliac joints (MRI-SI) and radiographs of the sacroiliac joints (radiograph-SI). They reported8 that of 230 patients with a positive ASAS classification, 17.4% did not have a diagnosis of axSpA. HLA-B27 positivity (OR 5.6) and any positive imaging (MRI-SI and/or radiograph-SI OR 34.3) were strong determinants of an axSpA diagnosis. That study points out that neither the presence of numerous SpA features nor fulfillment of the ASAS classification criteria automatically led to a diagnosis of axSpA. Moreover, positive imaging was considered particularly important in making a diagnosis of axSpA. In the Van Hoovels study, 80% of patients underwent imaging studies, and only 67% had both imaging and HLA testing.

A recent French nationwide study showed that rheumatologists’ confidence in the diagnosis of SpA in patients with CBP had limited agreement with classification criteria9. The authors concluded that currently, the best way to classify SpA should be the association of at least 1 classification criterion and a diagnosis of SpA according to the rheumatologist9.

Positive and negative predictive values (PPV and NPV) are the proportions of positive and negative results that are true positive and negative results, respectively. The PPV and NPV describe the clinical performance of a diagnostic test. However, when considering predictive values of diagnostic or screening tests, it is important to recognize the effect of the prevalence of disease in the study population. A test in a population with higher prevalence increases PPV. Conversely, increased prevalence results in decreased NPV. In the Van Hoovels study, the clinical diagnosis of SpA was reported in 52% of patients tested2. The clinical performance of FC to detect IBD is underscored by its very high NPV7. In the context of its added value to support a diagnosis of SpA, further prospective studies using rigorously classified SpA in cohorts with high and low prevalence of disease are needed. However, given their frequent coexistence, clinicians should be aware that FC testing is a useful tool for rheumatologists to screen for IBD in cases with an established diagnosis of SpA.

REFERENCES

  1. 1.↵
    1. Kopylov U,
    2. Starr M,
    3. Watts C,
    4. Dionne S,
    5. Girardin M,
    6. Seidman EG
    . Detection of Crohn disease in patients with spondyloarthropathy: the SpACE capsule study. J Rheumatol 2018;45:498–505.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Van Hoovels L,
    2. Van Den Bremt S,
    3. Schiemsky T,
    4. Cauchie M,
    5. Vander Cruyssen B,
    6. Bossuyt X,
    7. et al.
    Added value of fecal calprotectin to support the diagnosis of spondyloarthropathies. J Rheumatol 2019;46:215–6.
    OpenUrlFREE Full Text
  3. 3.↵
    1. van der Horst-Bruinsma IE,
    2. Nurmohamed MT
    . Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis 2012;4:413–22.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Atzeni F,
    2. Defendenti C,
    3. Ditto MC,
    4. Batticciotto A,
    5. Ventura D,
    6. Antivalle M,
    7. et al.
    Rheumatic manifestations in inflammatory bowel disease. Autoimmun Rev 2014;13:20–3.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Gionchetti P,
    2. Rizzello F
    . IBD: IBD and spondyloarthritis: joint management. Nat Rev Gastroenterol Hepatol 2016;13:9–10.
    OpenUrl
  6. 6.↵
    1. Olivieri I,
    2. Cantini F,
    3. Castiglione F,
    4. Felice C,
    5. Gionchetti P,
    6. Orlando A,
    7. et al.
    Italian expert panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev 2014;13:822–30.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Kopylov U,
    2. Rosenfeld G,
    3. Bressler B,
    4. Seidman E
    . Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis 2014;20:742–56.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Ez-Zaitouni Z,
    2. Bakker PA,
    3. van Lunteren M,
    4. Berg IJ,
    5. Landewé R,
    6. van Oosterhout M,
    7. et al.
    Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort. Ann Rheum Dis 2017;76:1086–92.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Gazeau P,
    2. Cornec D,
    3. Timsit MA,
    4. Dougados M,
    5. Saraux A
    . Classification criteria versus physician’s opinion for considering a patient with inflammatory back pain as suffering from spondyloarthritis. Joint Bone Spine 2018;85:85–91.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 2
1 Feb 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dr. Seidman replies
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dr. Seidman replies
ERNEST SEIDMAN
The Journal of Rheumatology Feb 2019, 46 (2) 216; DOI: 10.3899/jrheum.180833

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Dr. Seidman replies
ERNEST SEIDMAN
The Journal of Rheumatology Feb 2019, 46 (2) 216; DOI: 10.3899/jrheum.180833
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • To the Editor:
    • REFERENCES
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Interstitial Lung Disease?
  • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
  • Desk Rejections: Not Without Due Deliberation
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire